Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy?

AIMS To analyse the vasoreactivity of a coronary segment, previously scaffolded by the ABSORB bioresorbable vascular scaffold (BVS) device, in relationship to its intravascular ultrasound-virtual histology (IVUS-VH) composition and reduction in greyscale echogenicity of the struts. Coronary segments, transiently scaffolded by a polymeric device, may in the long-term recover a normal vasomotor tone. Recovery of a normal endothelial-dependent vasomotion may be enabled by scaffold bioresorption, composition of the underlying tissue, or a combination of both mechanisms. METHODS AND RESULTS All patients from the ABSORB Cohort A and B trials, who underwent a vasomotion test and IVUS-VH investigation at 12 and 24 months, were included. Acetylcholine (Ach) and nitroglycerin were used to test either the endothelial-dependent or -independent vasomotion of the treated segment. Changes in polymeric strut echogenicity-a surrogate for bioresorption-IVUS-VH composition of the tissue underneath the scaffold and their relationship with the pharmacologically induced vasomotion were all evaluated. Overall, 26 patients underwent the vasomotion test (18 at 12 and 8 at 24 months). Vasodilatory response to Ach was quantitatively associated with larger reductions over time in polymeric strut echogenicity (y= -0.159x- 6.85; r= -0.781, P< 0.001). Scaffolded segments with vasoconstriction to Ach had larger vessel areas (14.37 ± 2.50 vs. 11.85 ± 2.54 mm(2), P= 0.030), larger plaque burden (57.31 ± 5.96 vs. 49.09 ± 9.10%, P= 0.018), and larger necrotic core (NC) areas [1.39 (+1.14, +1.74) vs. 0.78 mm(2) (+0.20, +0.98), P= 0.006] compared with those with vasodilation. CONCLUSION Vasodilatory response to Ach, in coronary segments scaffolded by the ABSORB BVS device, is associated with a reduction in echogenicity of the scaffold over time, and a low amount of NC. In particular, the latter finding resembles the behaviour of a native coronary artery not caged by an intracoronary device.

[1]  B. Gersh,et al.  A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods , 2010 .

[2]  Patrick W Serruys,et al.  In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[3]  G. Mancini,et al.  Quantitative coronary angiography , 1994 .

[4]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[5]  G. D. De Meyer,et al.  Everolimus-Induced mTOR Inhibition Selectively Depletes Macrophages in Atherosclerotic Plaques by Autophagy , 2007, Autophagy.

[6]  E. Tuzcu,et al.  Coronary Plaque Classification With Intravascular Ultrasound Radiofrequency Data Analysis , 2002, Circulation.

[7]  E. Boerwinkle,et al.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. , 2003, Circulation.

[8]  Dong Bin Kim,et al.  Drug-eluting stent implantation could be associated with long-term coronary endothelial dysfunction. , 2007, International heart journal.

[9]  Frits Mastik,et al.  Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque , 2008, Circulation.

[10]  O. Hess,et al.  Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. , 2005, Journal of the American College of Cardiology.

[11]  D. Holmes,et al.  Segmental coronary endothelial dysfunction in patients with minimal atherosclerosis is associated with necrotic core plaques , 2009, Heart.

[12]  R. Whitbourn,et al.  Serial in vivo intravascular ultrasound-based echogenicity changes of everolimus-eluting bioresorbable vascular scaffold during the first 12 months after implantation insights from the ABSORB B trial. , 2011, JACC. Cardiovascular interventions.

[13]  Yoshinobu Onuma,et al.  Morphological and functional evaluation of the bioresorption of the bioresorbable everolimus-eluting vascular scaffold using IVUS, echogenicity and vasomotion testing at two year follow-up: a patient level insight into the ABSORB A clinical trial , 2010, The International Journal of Cardiovascular Imaging.

[14]  G. D. De Meyer,et al.  Selective clearance of macrophages in atherosclerotic plaques by autophagy. , 2007, Journal of the American College of Cardiology.

[15]  O. Muller,et al.  Interference of Drug-Eluting Stents With Endothelium-Dependent Coronary Vasomotion: Evidence for Device-Specific Responses , 2008, Circulation. Cardiovascular interventions.

[16]  P. Serruys,et al.  Three‐dimensional and quantitative analysis of atherosclerotic plaque composition by automated differential echogenicity , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[17]  R. Whitbourn,et al.  Comparison between the first and second generation bioresorbable vascular scaffolds: a six month virtual histology study. , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[18]  R. Whitbourn,et al.  Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold , 2011, The International Journal of Cardiovascular Imaging.

[19]  Bernard Chevalier,et al.  Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. , 2011, Journal of the American College of Cardiology.

[20]  P. Serruys,et al.  IVUS radiofrequency analysis in the evaluation of the polymeric struts of the bioabsorbable everolimus‐eluting device during the bioabsorption process , 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[21]  Bernard Chevalier,et al.  Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis: Six-Month Clinical and Imaging Outcomes , 2010, Circulation.

[22]  K. Robinson,et al.  Endothelium-dependent vasomotor dysfunction in pig coronary arteries with paclitaxel-eluting stents is associated with inflammation and oxidative stress , 2009 .

[23]  Patrick W Serruys,et al.  Monitoring in vivo absorption of a drug-eluting bioabsorbable stent with intravascular ultrasound-derived parameters a feasibility study. , 2010, JACC. Cardiovascular interventions.

[24]  P. Serruys,et al.  Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. , 2006, European heart journal.

[25]  G. Koehl,et al.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor , 2002, Nature Medicine.

[26]  S. Windecker,et al.  Vascular restoration therapy: what should the clinical and angiographic measures for success be? , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[27]  Patrick W Serruys,et al.  A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial , 2008, The Lancet.

[28]  Young-Hak Kim,et al.  Effects of statin treatments on coronary plaques assessed by volumetric virtual histology intravascular ultrasound analysis. , 2009, JACC. Cardiovascular interventions.

[29]  Antonio Colombo,et al.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. , 2003, Circulation.

[30]  John A Ormiston,et al.  First‐in‐human implantation of a fully bioabsorbable drug‐eluting stent: The BVS poly‐L‐lactic acid everolimus‐eluting coronary stent , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.